PharmiWeb

EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes

HONG KONG, Sep 17, 2025 - (ACN Newswire) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies ...
Nasdaq

Orthofix Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc With Other Clinical and Scientific Abstracts at the ISASS Annual Meeting

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the presentation of multiple clinical and scientific abstracts ...
Morningstar

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2025 to be held from ...
ksn.com

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

Data to be Presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Supports neffy’s potential to be a safe and ...